Evaluating Health-Related Quality of Life in Interstitial Lung Disease Patients With and Without Lung Transplantation Using the GR-Scale - Report - MDSpire

Evaluating Health-Related Quality of Life in Interstitial Lung Disease Patients With and Without Lung Transplantation Using the GR-Scale

  • By

  • Sina Stoltefuß

  • Gabriela Leuschner

  • Tobias Veit

  • Jeremias Götschke

  • Katrin Milger

  • Teresa Kauke

  • Alexandra Lenoir

  • Nikolaus Kneidinger

  • Jürgen Behr

  • January 10, 2026

  • 0 min

Share

Clinical Report: Evaluating Health-Related Quality of Life in ILD Patients

Overview

This study evaluates health-related quality of life (HRQoL) in interstitial lung disease (ILD) patients, comparing those who have undergone lung transplantation (LTx) with non-transplanted patients. It highlights the impact of chronic lung allograft dysfunction (CLAD) on HRQoL post-transplant.

Background

Interstitial lung diseases significantly impair health-related quality of life due to debilitating symptoms such as shortness of breath and fatigue. Lung transplantation is a critical intervention for advanced ILD, aiming to enhance both survival and HRQoL. Understanding the nuances of HRQoL in these patients is essential for improving clinical outcomes and patient care.

Data Highlights

No numerical data or trial data provided in the source material.

Key Findings

  • ILD symptoms, including cough and fatigue, progressively worsen, impacting HRQoL.
  • Lung transplantation can significantly improve HRQoL in selected patients with severe ILD.
  • Chronic lung allograft dysfunction (CLAD) negatively affects HRQoL post-transplant.
  • Patient-reported outcome measures (PROMs) are crucial for capturing the patient experience in ILD.
  • Improved HRQoL post-LTx may decline over time due to various complications.

Clinical Implications

Healthcare providers should prioritize the assessment of HRQoL in ILD patients, particularly those undergoing lung transplantation. Utilizing PROMs can provide valuable insights into patient experiences and guide treatment decisions. Monitoring for CLAD is essential to address its impact on quality of life.

Conclusion

The study underscores the importance of evaluating HRQoL in ILD patients, particularly in the context of lung transplantation and the challenges posed by CLAD. Continuous assessment of patient-reported outcomes is vital for optimizing care.

References

  1. Post-Liver Transplantation Outcomes: Quality of Life, Work Capacity, and Employment Reinstatement in Patients, Springer, 2021 -- Title
  2. Interstitial Lung Disorders Following Hematopoietic Stem Cell Transplantation: A Novel Presentation of Chronic Graft-Versus-Host Disease?, Nature, 2022 -- Title
  3. Long-term Quality of Life Outcomes Reported by Patients After Allogeneic Hematopoietic Cell Transplantation, Nature, 2025 -- Title
  4. Approach to the Evaluation and Management of Interstitial Lung Abnormalities: An Official American Thoracic Society Clinical Statement, American Journal of Respiratory and Critical Care Medicine, 2025 -- Title
  5. Improvements in Patient-Reported Functioning after Lung Transplant is Associated with Improved Quality of Life and Survival, PubMed, 2025 -- Title
  6. Bone Marrow Transplantation — Characteristics of Transplants and Patient-Reported Lung Health in Swiss Survivors of Childhood Cancer Following Hematopoietic Stem Cell Transplantation: A Cohort Analysis
  7. Approach to the Evaluation and Management of Interstitial Lung Abnormalities: An Official American Thoracic Society Clinical Statement | American Journal of Respiratory and Critical Care Medicine
  8. Improvements in Patient-Reported Functioning after Lung Transplant is Associated with Improved Quality of Life and Survival - PubMed
  9. https://bmcpulmmed.biomedcentral.com/counter/pdf/10.1186/s12890-024-03262-9.pdf

Original Source(s)

Related Content